FN2 Earnings Intelligence
JNJ revenue earnings history
Johnson & Johnson (JNJ) quarterly reported and estimated revenue history by fiscal quarter.
Earnings History
Johnson & Johnson
J&J's raised outlook and resilient Innovative Medicine growth support the near-term operating case, but the evidence is mixed: MedTech remains comparatively weak and execution, regulatory timing, acquisition costs and litigation continue to matter.
Johnson & Johnson
Johnson & Johnson delivered a solid Q2 2026 with $25.3 billion in sales (5.6% operational growth) and a $400 million raise in full-year guidance to a $101.1 billion midpoint. EPS of $2.90 beat the $2.84 consensus by 2.1%. The quarter was anchored by strong uptake of newly launched products across both Innovative Medicine (ICOTYDE, INLEXZO, RYBREVANT) and MedTech (VARIPULSE, vision lenses), with oncology remaining a primary growth engine through DARZALEX, CARVYKTI, and TALVEY. Despite the beat and raise, shares declined 2.7% on the report session, partially reflecting MedTech cardiovascular headwinds and STELARA biosimilar erosion, before recovering 7.7% over the subsequent period. Management's confident tone and continued pipeline execution (Firefly Bio acquisition, OTTAVA robotics, milvexian readout) reinforce the trajectory toward double-digit growth by decade's end.
Johnson & Johnson
J&J's beat and guidance raise rest on launch momentum in Innovative Medicine (ICOTYDE, INLEXZO) and MedTech (VARIPULSE Pro, TECNIS PureSee), plus execution toward the planned mid-2027 Orthopedics separation. Management's double-digit-growth-by-decade-end ambition and $55B U.S. manufacturing commitment underpin a confident tone. The stock did not hold an outsized reaction on the day (a modestly negative abnormal move) and has drifted lower since, so the thesis is one of execution risk against an ambitious outlook rather than a clean fundamental win.
Johnson & Johnson
The supplied analyses support a constructive but conditional view: J&J is pursuing growth through launches, pipeline investment, acquisitions, and a higher-growth MedTech mix, while execution and legal, tariff, competitive, and regulatory risks remain significant.
Johnson & Johnson
The supplied analysis strengthens the case that diversified product growth, pipeline launches, and MedTech expansion can support J&J’s operating trajectory. That constructive view is tempered by persistent STELARA erosion, litigation, policy exposure, and execution risk around the orthopaedics separation and regulatory pipeline.
Johnson & Johnson
The supplied analysis supports a constructive but conditional view: diversified demand, pipeline progress, and medtech expansion can support continued growth, while product erosion, cost pressures, and execution risks test its durability.
Johnson & Johnson
The quarter supports a constructive but qualified view: diversified growth, pipeline progress, acquisitions, and higher guidance provide offsets to STELARA erosion, tariffs, and execution risks.
Get the JNJ recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.